Remifentanil analgosedation in preterm newborns during mechanical ventilation

Area of Science:

• Neonatalogy
• Pharmacology
• Critical Care Medicine

Background:

• Preterm infants on mechanical ventilation often require analgesia and sedation.
• Assessing effective and safe opioid options is crucial for this vulnerable population.

Purpose of the Study:

• To evaluate the efficacy and safety of remifentanil for analgesia and sedation in preterm neonates undergoing mechanical ventilation.

Main Methods:

• A continuous intravenous infusion of remifentanil was administered to 48 preterm infants requiring mechanical ventilation.
• Dose requirements, extubation time, and side effects were monitored.

Main Results:

• Remifentanil significantly reduced pain and sedation scores within 1 hour.
• An adjusted dose of 0.094 microg/kg/min provided adequate analgesia in 97% of infants.
• Mean extubation time was 36 minutes with no respiratory or cardiovascular side effects observed.

Conclusions:

• Remifentanil is a manageable and effective opioid for preterm neonates on mechanical ventilation.
• Further randomized controlled trials are recommended to confirm long-term outcomes.